P676 Faecal monitoring is useful in monitoring treatment response in anti-TNF-treated patients
ECCO'20 Vienna
2020
P677 It’s time to grow up: what is it like to transition from the paediatric to adult inflammatory bowel disease service?
ECCO'20 Vienna
2020
P678 Effect of accelerated infliximab induction on short-term outcomes of paediatric acute severe ulcerative colitis
ECCO'20 Vienna
2020
P679 What is the best strategy after failure to anti-TNF? Ustekinumab or other anti-TNF?
ECCO'20 Vienna
2020
P681 Efficacy of vedolizumab for the prevention of postoperative recurrence in Crohn’s disease: Data from clinical practice from the ENEIDA registry
ECCO'20 Vienna
2020
P685 Healthcare resource use associated with ferric maltol and IV iron treatment for iron deficiency anaemia in patients with inflammatory bowel diseaseECCO'20 Vienna
2020
P686 Expression of CD39 ectonucleotidase on regulatory T cells and on T helper 17 cells in children with IBD receiving anti-TNF therapy
ECCO'20 Vienna
2020
P687 Early and sustained improvement in stool frequency and rectal bleeding following 52 weeks of mirikizumab treatment
ECCO'20 Vienna
2020
P689 Patient-reported outcomes (PRO-2) and intestinal ultrasound in ulcerative colitis patients: subanalysis of the TRUST&UC study cohort
ECCO'20 Vienna
2020